Docosatetraenoylethanolamide

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Icebob99 (talk | contribs) at 14:43, 3 January 2017 (added stub tag). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Docosatetraenoylethanolamide
Names
IUPAC name
(7Z,10Z,13Z,16Z)-N-(2-hydroxyethyl)docosa-7,10,13,16-tetraenamide
Other names
DEA
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
  • InChI=1S/C24H41NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-24(27)25-22-23-26/h6-7,9-10,12-13,15-16,26H,2-5,8,11,14,17-23H2,1H3,(H,25,27)/b7-6-,10-9-,13-12-,16-15- checkY
    Key: FMVHVRYFQIXOAF-DOFZRALJSA-N checkY
  • CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)NCCO
Properties
C24H41NO2
Molar mass 375.59 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Docosatetraenoylethanolamide (DEA) is an endogenous ethanolamide that has been shown to act on the cannabinoid (CB1) receptor.[1] DEA is similar in structure to anandamide (AEA, a recognized endogenous ligand for the CB1 receptor), containing docosatetraenoic acid in place of arachidonic acid. While DEA has been shown to bind to the CB1 receptor with similar potency and efficacy as AEA, its role as a cannabinergic neurotransmitter is not well understood.

References

  1. ^ Hanus, L.; Gopher, A.; Almog, S.; et al. (1993). "Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor". J Med Chem. 36 (20): 3032–3034. doi:10.1021/jm00072a026. PMID 8411021.